Kucha tea

Synopsis

Kucha Tea (Camellia assamica var. kucha): A Comprehensive Reference

Identity and Botanical Classification

Kucha tea is a rare, botanically distinct variety of the tea plant whose formal taxonomic designation has undergone revision. Theacrine, the primary bioactive compound derived from it, is found in Camellia kucha Hung T. Chang (a wild tea plant species, formerly named Camellia assamica var. kucha); the compound's full chemical name is 1,3,7,9-tetramethyl-1H-purine-2,6,8(3H,7H,9H)-trione, with the chemical formula C₉H₁₂N₄O₃ and a molecular weight of 224.22. The plant is also widely referred to by the chemical synonym 1,3,7,9-tetramethyluric acid.

Two types of Chinese Kucha (bitter) tea are traditionally consumed for health improvement; one is Kuding tea prepared from leaves of Ligustrum robustum or Ilex kaushue, and the other is Yunnan Kucha tea prepared from young leaves of Camellia assamica var. kucha Chang et Wang. The plant, naturally grown in certain mountain areas of Yunnan, China, is assumed to be a mutant variety of the wild Pu'er tea plant (Camellia sinensis var. assamica); thus, Yunnan Kucha tea is also called bitter Pu'er tea or Pu'er Kucha tea.

In Chinese, the word "Kucha" means bitter tea, a name that directly reflects the plant's notably bitter taste profile, which arises from its unusually high alkaloid content. The plant is sometimes also rendered as Ku cha, Camellia kucha, or simply "bitter Pu'er tea" in the scientific literature.

Kucha tea (Camellia assamica var. kucha) is a lesser-known yet historically significant variety of tea native to select regions in China, particularly Yunnan Province. The kucha variety of tea is the primary source of naturally occurring theacrine and produces the chemical in higher concentrations than other known plants; interestingly, theacrine has not been detected at all in more traditional tea strains. However, it has recently been detected in small quantities in certain other plants, including Camellia sinensis var. puanensis, Ilex vomitoria, and Camellia gymnogyna.

Common Forms and Preparations

Kucha tea is available in several forms, each reflecting different degrees of processing:

Whole-leaf tea (traditional infusion): The dried young leaves are steeped in hot water to produce a bitter tea. Young kucha tea plant leaves contain higher concentrations of both theacrine (1.3–3.6% of dry weight) and caffeine (0.6–2.7% of dry weight) compared to mature leaves; for example, a 2-gram teabag containing Kucha tea leaves may yield only 20.8–57.6 mg of theacrine.
Standardized extracts: Bitter tea extract derived from the leaves of the kucha variety is available as a specialized botanical ingredient standardized to contain a defined percentage of theacrine — commonly 40%, 60%, or higher.
Isolated theacrine (TeaCrine®, iTeaCrine®): The extraction process includes drying the kucha leaves, followed by water extraction, precipitation of tea polyphenols, and further purification using silica gel column chromatography; this method produces natural theacrine with a purity of over 95%. Branded forms such as TeaCrine® are nature-identical, chemically equivalent versions of theacrine.
Capsules and powders: Theacrine isolated from kucha tea is marketed in capsule and powder form as a standalone supplement and is incorporated into multi-ingredient pre-workout, energy, and nootropic formulas.

Geographic Origin and Botanical Character

The kucha tea plant (Camellia assamica var. kucha) comes from the Yunnan province of China, where it has been domesticated and used medicinally for well over two millennia. Technically a mutant version of the wild Pu'er tea plant, indigenous peoples use kucha tea to treat viral infections like colds and flus, and several 1,000-plus-year-old kucha tea trees are reportedly still alive and used to this day.

Theacrine, a purine alkaloid with a chemical structure similar to caffeine, was first identified as a minor constituent in the tea plant (Camellia sinensis L.), and then detected as a relatively abundant component in Yunnan Kucha tea. Besides morphological similarity between the wild Pu'er plant and the Yunnan Kucha plant, chemical constituent analysis of their tea infusions supports that the Yunnan Kucha plant is a mutant variety of the wild Pu'er plant.

Traditional and Historical Use

The kucha tea plant comes from the Yunnan province of China, where it has been domesticated and used medicinally for well over two millennia. Yunnan Kucha (bitter) tea, prepared from a mutant variety of the wild Pu'er tea plant, is assumed to possess superior anti-influenza activity according to the empirical utilization of indigenous aborigines in certain uncultivated mountain areas of Yunnan.

Bitter Pu'er Kucha tea was consumed as an herbal tea by Aboriginal people in Yunnan, China when experiencing a cold. Historically, Camellia assamica has been commonly consumed in the form of teas made from the leaves by Chinese rainforest cultures as an anti-inflammatory agent as well as a pain reliever, and it is theorized that theacrine in this plant is mainly responsible for these positive effects.

A rare variety of tea plant traditionally grown in specific regions of China, kucha tea has been consumed for centuries in local cultures, valued for its unique flavor and purported health-promoting properties. Indigenous communities have prized Kucha tea for its unique medicinal properties, distinguishing it from other tea varieties by its naturally high content of the alkaloid theacrine. Traditional healers and herbalists have long incorporated Kucha tea into remedies to address fatigue, improve mental clarity, and promote overall vitality.

It is important to note that the traditional record for kucha tea as a distinct botanical is largely separate from the extensive modern scientific literature focused on its isolated alkaloid, theacrine. Traditional use was of the whole leaf as a bitter beverage tea; the modern supplement industry's use of isolated, highly purified theacrine is a contemporary development.

Key Constituents and Active Compounds

The leaves of Camellia assamica var. kucha Chang et Wang have been studied by many Chinese researchers, and at least ten compounds were isolated and identified from the leaves: theacrine, caffeine, theobromine, catechin, epigallocatechin, gallocatechin, epigallocatechin-3-O-gallate, gallocatechin 3-O-gallate, 1,2,6-tri-O-galloyl-β-D-glucose, and gallic acid.

Among these, the most scientifically studied are:

Theacrine (1,3,7,9-tetramethyluric acid): A naturally occurring alkaloid found in the leaves of the Camellia kucha tea plant. It is the primary compound of interest in modern dietary supplement research.
Strictinin: A hydrolysable ellagitannin generally present as a minor constituent in various teas but detected as a relatively abundant compound in Pu'er Kucha tea. Strictinin has attracted scientific interest for antiviral properties.
Methylliberine: There are two nootropic compounds in the kucha plant that are either not found in other varieties of tea leaves or are not found in the same concentration — these are theacrine and methylliberine.
Caffeine and theobromine: Present alongside theacrine; the more common tea-related purine alkaloids include caffeine, theobromine, theophylline, and theacrine.
Polyphenols and catechins: Including epigallocatechin gallate and related compounds common to the Camellia genus.

Biosynthesis of Theacrine

Theacrine is synthesized naturally in the kucha plant from caffeine through a three-step biochemical pathway; this transformation imparts theacrine with unique properties that differentiate it from caffeine while maintaining some of the stimulant effects. More specifically, while still developing, the plant first converts theobromine into caffeine and then converts theobromine and caffeine into theacrine. Theacrine is converted from caffeine by hydration, oxidation, and methylation, and it is thought to influence the central nervous system as a neuroactive ingredient.

Mechanisms of Action

The scientific literature on kucha tea's bioactivity is almost entirely focused on its primary alkaloid, theacrine. Multiple receptor systems and intracellular signaling pathways have been implicated:

Adenosine Receptor Antagonism

Theacrine (1,3,7,9-tetramethyluric acid) is a pure alkaloid with a similar structure to caffeine and acts comparably as an adenosine receptor antagonist. In animal research, pre-treatment with theacrine significantly attenuated the motor depression induced by adenosine receptor agonists, indicating that theacrine is likely acting as an adenosine receptor antagonist. Theacrine acts as an adenosine receptor antagonist to play a role in locomotor activation and fatigue reduction. Specifically, adenosine plays an important role in biochemical processes that promote fatigue, sedation, and relaxation; by inhibiting the activity of the A1 and A2A receptors, theacrine may help decrease perceived feelings of fatigue.

Dopaminergic Signaling

Researchers examined the role of dopamine D₁ and D₂ receptor antagonism on theacrine-induced hyperlocomotion; both antagonists — D₁R SCH23390 and D₂R eticlopride — significantly reduced theacrine-stimulated activity, indicating that this behavioral response is at least in part mediated by DA receptors. High doses of theacrine also activate dopamine D1 and D2 receptors in rats; activation of these receptors is responsible for motivation and wakefulness.

Antioxidant Pathways

Theacrine upregulates the expression of SIRT3 and activates the SIRT3/FOXO3/SOD2 signaling pathway, resulting in antioxidant efficiency. In experimental models, theacrine increased the production of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and reduced the activity of xanthine oxidase.

Anti-Inflammatory Pathways

Theacrine upregulates the expression of RNA and protein of SMAD3, p-ERK, and p-p38, and downregulates the expression of NF-κB and IL-6, showing anti-inflammatory effects.

Cognitive and Metabolic Effects

Theacrine regulates brain glucose metabolism, inhibits phosphodiesterases, and restores the levels of 5-HTP and dopamine to improve cognitive capacity. For lipid metabolism, theacrine ameliorates lipid metabolism by activating the SIRT3/AMPK/ACC pathway and downregulating the mRNA and protein levels of fatty acid synthase, fatty acid translocase, stearoyl-CoA desaturase-1, lipoprotein lipase, and acetyl-CoA carboxylase-1.

Dose-Dependent Biphasic Activity

An important and unusual pharmacological feature of theacrine is apparent dose-dependent duality: results from rodent models suggest that theacrine might regulate the adenosine system at lower doses to increase sleep; however, this may or may not apply to humans. Theacrine possesses potent sedative and hypnotic properties at certain doses, and its central nervous system effects are mediated through the adenosine system. At higher doses, the stimulatory, locomotor-activating effects appear to predominate via dopaminergic pathways.

Scientific Evidence by Area of Use

Energy, Fatigue, and Physical Performance

The largest body of human clinical evidence for kucha-derived theacrine concerns subjective energy and fatigue. As a first step in a series of experiments, researchers examined the effects of TeaCrine™ (theacrine, 1,3,7,9-tetramethyluric acid) in humans; using a randomized, double-blinded, within-subject (crossover) design, 15 healthy subjects volunteered to ingest 200 mg of TeaCrine™ or placebo, with anchored VAS questionnaires used to detect changes in various aspects of physical and mental energy and performance.

A subset of 6 subjects underwent a separate 7-day, open-label, repeated-dose study comparing 100 mg, 200 mg, and 400 mg of theacrine.

In a widely cited 2015 placebo-controlled study: theacrine is a purine alkaloid found primarily in the leaves of the Camellia kucha plant; to compare the effects of a theacrine-containing dietary supplement with caffeine and placebo on energy and mood, 10 healthy men (20.8 ± 0.7 years) and 10 healthy women (22.2 ± 1.1 years) ingested the dietary supplement TheaTrim (containing a branded form of theacrine, TeaCrine™, and 150 mg caffeine), caffeine only (150 mg), or a placebo on three different days, separated by approximately one week. No condition or interaction effects were noted for trail making test, digit symbol substitution test, or reaction time, despite a trend for improvement in selected variables with both TheaTrim and caffeine treatment; however, condition effects or trends were noted for subjective feelings, with values for attentive, alert, focused, and energetic higher for TheaTrim than for placebo and caffeine. Acute intake of the theacrine-containing dietary supplement did not significantly alter heart rate or blood pressure in healthy men or women; neither the supplement nor caffeine alone improved cognitive performance in a statistically significant manner, but TheaTrim did appear to favorably impact multiple subjective feelings related to energy and mood compared to caffeine and placebo.

A second human clinical investigation employed a five-arm crossover design: 24 men and 26 women ingested a placebo, theacrine at 25 mg, theacrine at 125 mg, caffeine at 150 mg, or a combination of 125 mg theacrine and 150 mg caffeine on five separate occasions separated by approximately one week; subjects rated their subjective feelings using a 10 cm visual analog scale, and subjective feelings of attentiveness, sense of focus, and sense of energy improved with all active treatments. These findings indicate that theacrine, when used alone at 125 mg or in combination with caffeine, is safe and effective at improving subjective feelings related to energy in healthy men and women; moreover, the combination of theacrine and caffeine may improve cognitive performance as assessed by the trail making test.

For athletic performance specifically, theacrine's role appears limited. A soccer-based study assessed early non-habituating effects including increases in energy and focus in response to TeaCrine®, and studied its effects compared with caffeine on cognitive performance and time-to-exhaustion during a simulated soccer game in high-level male and female athletes.

Evidence strength: Human clinical evidence for subjective energy and mood is preliminary but consistent across several small-to-moderate randomized controlled trials (total n typically under 60 per study). Objective performance improvements (reaction time, cognitive test scores) are less consistently demonstrated and often do not reach statistical significance. Larger, independent replication studies are needed.

Cognitive Function

A 2024 placebo-controlled, double-blind, randomized crossover study from Australian Catholic University examined both dose and timing effects: participants completed seven conditions including a placebo and 100 mg and 400 mg of theacrine administered at 12, eight, and four hours prior to bedtime; the doses chosen were based on a typical caffeine dose (100 mg) and the recommended upper daily limit of caffeine (400 mg). Consuming theacrine within eight hours of bedtime improved next-morning cognitive performance, with the 400 mg dose reducing the number of lapses on the Psychomotor Vigilance Task, although there were no significant effects on reaction time. The authors concluded that their findings provide initial scientific evidence suggesting that theacrine consumption may improve some aspects of next-morning cognitive performance but not others, with small non-significant effects on nighttime sleep.

Theacrine (1,3,7,9-tetramethyluric acid) is thought to act through both the adenosine and dopamine systems to provide a mild stimulant effect, as well as a calming effect.

Evidence strength: The cognitive evidence base is preliminary. A handful of small human trials show trends toward improved subjective alertness and selective next-morning task performance at specific doses, but objective cognitive improvements across standardized test batteries are inconsistent.

Antiviral Activity

Several peer-reviewed studies have examined the traditional use of Yunnan Kucha tea for colds in a scientific context. Comparative analysis indicates that theacrine and strictinin are two major ingredients responsible for the anti-influenza activity of Yunnan Kucha tea. Both theacrine and strictinin were shown to possess an inhibitory potency against the human influenza virus A/Puerto Rico/8/34, while chlorogenic acid only displayed weak inhibition; it was concluded that theacrine and strictinin were active ingredients in the anti-influenza activity of Pu'er Kucha tea, with strictinin possessing higher inhibitory potency against the human influenza virus than theacrine.

Research has also extended to coronavirus surrogates: a study aimed to evaluate the effects of these tea compounds on the infection of mouse hepatitis virus (MHV), a β-coronavirus serving as a surrogate for SARS-CoV; treatment with strictinin (100 μM), but not theacrine, completely eliminated MHV infection, as indicated by a pronounced reduction in plaque formation, nucleocapsid protein expression, and progeny production of MHV. It has been shown that strictinin could prevent replication of human, duck, and swine influenza A viruses in vitro at non-toxic concentrations, putatively by reacting with the viral particles to inhibit viral entry in the initial stage.

Evidence strength: This research is entirely in vitro (cell-based assays) or conducted in animal models. No human clinical trials on kucha tea or its constituents for influenza or any viral infection have been published. This evidence cannot be used to draw conclusions about clinical efficacy in humans.

Anti-Inflammatory and Analgesic Effects

Theacrine has been reported to have antioxidant, anti-inflammatory/analgesic, anti-depressive, locomotor, and sedative/hypnotic properties. In rodent studies, theacrine reduced inflammation in mice with a potency comparable to or lesser than the anti-inflammatory drug indomethacin, with pain-relieving properties that were dose-dependent; the same study showed that caffeine had no effect on neither inflammation nor pain in mice. From human-oriented clinical patent literature, theacrine itself can reduce biomarkers of inflammation in humans in response to acute inflammatory stressors (e.g., intense exercise) or chronic consumption, and has been reported to decrease C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), and TNF-alpha.

Studies in mice suggest that theacrine may have anti-inflammatory and antioxidant properties: it protected against liver damage by reducing the levels of inflammatory cytokines IL-1β, TNF-α, IL-6, and IFN-γ in the liver, and also increased the antioxidant capacity of the blood and liver of stressed mice.

Evidence strength: Anti-inflammatory and analgesic evidence is largely preclinical (animal and in vitro). Human data on inflammatory biomarker reductions are cited in patent applications and have not been independently replicated in peer-reviewed randomized controlled trials of sufficient size.

Lipid Metabolism and Body Composition

Some studies suggest theacrine may serve as an effective antioxidant, anti-inflammatory agent, and may have anti-obesity properties. Mechanistically, theacrine's effects on fat metabolism have been studied in animal and cell models via the SIRT3/AMPK/ACC pathway and downregulation of the mRNA and protein levels of fatty acid synthase, fatty acid translocase, stearoyl-CoA desaturase-1, lipoprotein lipase, and acetyl-CoA carboxylase-1.

Evidence strength: Preclinical only. No published human clinical trials on theacrine for lipid metabolism or body composition have been identified in peer-reviewed literature.

Locomotor Activity and Physical Endurance

Animal pharmacology research has documented theacrine's motor-activating properties: theacrine enhanced activity levels in a dose-dependent manner, implicating a role of the nucleus accumbens in modulating its effects on locomotion; additionally, theacrine did not induce locomotor sensitization or tolerance after chronic exposure; taken together, these findings demonstrate that theacrine significantly enhances activity, an effect mediated by both the adenosinergic and dopaminergic systems.

Evidence strength: Preclinical animal research demonstrates clear locomotor-activating effects via dual receptor mechanisms. Human translation of these findings has been tested in several small trials with mixed results on objective physical performance endpoints.

Sleep and Sedative-Hypnotic Effects

Theacrine possesses potent sedative and hypnotic properties, and its central nervous system effects are mediated through the adenosine system. In the 2024 Scientific Reports randomized crossover trial of 22 healthy males: no significant effect of the low or high theacrine dose on subsequent sleep was found, although the high dose showed small non-significant effects on sleep efficiency and wake after sleep onset at each timepoint of consumption. Theacrine consumption had no significant effect on objective sleep compared to placebo, regardless of the dose or timing. No adverse events were reported during the data collection.

Evidence strength: The sedative-hypnotic effects identified in animal models at low doses have not been confirmed in human trials; rather, the available human sleep-architecture data shows no significant disruption of sleep, even at doses up to 400 mg, which is a noteworthy safety-relevant finding distinct from caffeine's known sleep-disrupting properties.

Body Systems Associated with Kucha Tea Constituents

Based on available peer-reviewed research, kucha tea's key constituents — principally theacrine and strictinin — have been studied in relation to the following body systems:

Central nervous system: Adenosinergic and dopaminergic modulation; subjective energy, mood, alertness, and motivation.
Immune system / antiviral defense: In vitro inhibition of influenza A and β-coronavirus surrogates by theacrine and strictinin.
Musculoskeletal / locomotor system: Animal evidence for locomotor activation and anti-fatigue effects; preliminary human data on energy and exercise motivation.
Hepatic (liver) system: Animal data on anti-inflammatory and antioxidant protection, including reduction of hepatic inflammatory cytokines.
Cardiovascular system: Human studies show largely no significant effect on heart rate or blood pressure at doses up to 300–400 mg.
Metabolic / lipid system: Preclinical evidence for effects on lipid metabolism pathways (SIRT3/AMPK/ACC).
Renal (kidney) system: Monitored in the 8-week safety trial as a clinical safety marker; remained within normal limits at doses of 200 and 300 mg/day.

A 2020 review in Frontiers in Nutrition summarized the broad scope of research: the review examined the advances in research on the health beneficial effects of theacrine, including antioxidant effect, anti-inflammatory effect, locomotor activation and fatigue reduction, improving cognitive effect, hypnotic effect, ameliorating lipid metabolism, and inhibiting breast cancer cell metastasis effect; the inconsistent results in this research field and further expectations were also discussed.

Dosages Reported in Human Clinical Studies

The following dosages appear in peer-reviewed or formally published clinical research on theacrine derived from kucha tea:

200 mg of TeaCrine™ (theacrine) as a single dose in a randomized, double-blinded, crossover pilot trial of 15 healthy subjects.
100 mg, 200 mg, and 400 mg of theacrine in a separate 7-day, open-label, repeated-dose substudy of 6 subjects.
25 mg and 125 mg of theacrine alone, or 125 mg in combination with 150 mg caffeine, in a 50-participant (24 men, 26 women) five-arm crossover study.
200 mg/day (low-dose group, n=19) and 300 mg/day (high-dose group, n=21) of TeaCrine® ingested once daily for 8 weeks in a safety trial of 60 healthy men and women.
25 mg and 125 mg of theacrine (as TeaCrine®), 150 mg caffeine, or the combination of 125 mg theacrine and 150 mg caffeine in a pharmacokinetic drug interaction study of 8 healthy adults.
100 mg and 400 mg of theacrine administered at 12, 8, and 4 hours prior to bedtime in a 2024 randomized crossover sleep and cognition study of 22 healthy males.

Regarding naturally occurring kucha tea leaf preparations, one commercial whole-leaf supplement used 1,000 mg of Camellia kucha tea leaves standardized for 5% theacrine, equating to 50 mg of active theacrine.

Safety Considerations

Acute Toxicity

Brief results of an acute toxicity study in mice calculated the LD₅₀ of orally administered theacrine as 810.6 mg/kg body weight (95% confidence interval: 769.5–858.0 mg/kg body weight). Kucha tea, a natural source of theacrine, has been consumed in China for thousands of years without any seriously reported side effects.

Eight-Week Safety in Humans

The most rigorous safety data come from a dedicated 8-week randomized controlled trial: all values for clinical safety markers fell within normal limits and no group × time interactions were noted; no evidence of habituation was noted as baseline values for energy, focus, concentration, anxiety, motivation to exercise, and POMS remained stable in all groups across the 8-week study protocol. These findings support the clinical safety and non-habituating neuro-energetic effects of TeaCrine® supplementation over eight weeks of daily use (up to 300 mg/day); moreover, there was no evidence of a tachyphylactic response typical of neuroactive agents such as caffeine and other stimulants.

Primary outcomes monitored included fasting clinical safety markers (heart rate, blood pressure, lipid profiles, hematologic blood counts, biomarkers of liver/kidney/immune function) and energy, focus, concentration, anxiety, motivation to exercise, and POMS.

Cardiovascular Safety

Multiple human studies have assessed hemodynamic responses to theacrine. Heart rate and blood pressure were largely unaffected by theacrine treatment. Acute intake of the theacrine-containing dietary supplement did not significantly alter heart rate or blood pressure in healthy men or women. In the 2024 sleep/cognition trial, no adverse events were reported during the data collection.

Pharmacokinetic Interaction with Caffeine

A clinically relevant interaction between theacrine and caffeine has been formally documented. Caffeine co-administration increased the maximum plasma concentration and area under the curve of theacrine without altering theacrine's half-life; theacrine had no impact on caffeine or paraxanthine pharmacokinetics. Co-administration of theacrine and caffeine results in a clinically significant pharmacokinetic interaction — namely, increased theacrine exposure; enhanced oral bioavailability is the most likely mechanism by which caffeine alters theacrine exposure. However, hemodynamic parameters were unaltered despite the pharmacokinetic interaction, suggesting that co-administration of caffeine and theacrine is safe at the doses administered.

Because caffeine substantially increases theacrine's plasma exposure, individuals combining kucha-derived theacrine supplements with caffeine-containing beverages or products may be exposed to meaningfully higher theacrine levels than when taking theacrine alone.

Genotoxicity Concern (Preclinical)

Similar to other purine alkaloids, theacrine was reported to induce chromosomal aberrations in onion root tips, in Vicia faba cells treated during the G2 stage of interphase, and in Chinese hamster cells. The clinical relevance of these in vitro genotoxicity signals in the context of the doses used in human supplementation has not been established in published peer-reviewed literature.

Multi-Ingredient Supplement Limitation

A recurring methodological limitation in the human clinical literature is that theacrine has limited scientific studies compared to caffeine; it is often formulated as part of multi-ingredient supplements, making it difficult to isolate its specific effects. The available human clinical research constitutes only a small number of trials, some of which evaluated theacrine within a multi-ingredient dietary supplement.

Population Limitations of Available Data

All published human safety and efficacy data on theacrine/kucha tea extracts were conducted in healthy young adults. Although theacrine is similar in structure to caffeine, more research is needed to assess the safety of theacrine in special populations, including pregnant or lactating individuals, older adults, those with cardiovascular or liver disease, and individuals on medications metabolized through pathways relevant to purine alkaloids.

Relationship Between Whole Kucha Tea and Isolated Theacrine

It is critical to distinguish between whole kucha tea leaf preparations and isolated theacrine. Some studies suggest theacrine may have beneficial qualities, and in the studies involving theacrine, beneficial effects may be at least partially attributable to an assortment of purine alkaloids and phenolic compounds. The whole leaf contains strictinin, catechins, chlorogenic acid, methylliberine, and other bioactive compounds alongside theacrine. Published clinical trials have exclusively used either isolated theacrine (as TeaCrine® or iTeaCrine®) or multi-ingredient supplements containing standardized theacrine — not whole kucha tea leaves. This means that findings from clinical research cannot be automatically extended to the whole-leaf tea beverage and vice versa.

Methylliberine: A Secondary Kucha Compound

Methylliberine and theacrine are methylurates found in the leaves of various Coffea species and Camellia assamica var. kucha, respectively. Human pharmacokinetic research has shown that methylliberine exhibited linear pharmacokinetics that were unaffected by co-administration of either caffeine or theacrine. In a human trial, methylliberine significantly improved subjective feelings of energy, concentration, motivation, and mood, but not cognitive function; placebo improved motivation and mood at hours 1 and 2, while methylliberine sustained benefits for longer; methylliberine also improved concentration, well-being, and the ability to tolerate stress to a greater degree than placebo while having no detrimental effects on vital signs.

Regulatory Status and Commercial Context

Kucha tea and its extracted constituents (primarily theacrine) are marketed globally as dietary supplement ingredients. A pure form of theacrine has been extracted and is being tested for possible usefulness as a supplement, and is used in sports nutrition supplements in the categories of pre-workout and fat burners. The branded ingredient TeaCrine® is manufactured by Compound Solutions Inc. and represents the most studied commercial form. Neither kucha tea nor theacrine currently holds monograph status from the WHO, ESCOP, German Commission E, or the European Pharmacopoeia as of the available published literature. No EFSA or NIH Office of Dietary Supplements monograph on kucha tea or theacrine specifically was identified in the sources reviewed.